What our 2010 trends report say about you

I'd say 2010 was more than an interesting year in pharma manufacturing.

This issue contains a little collection of the big story topics of the year, with links to representative stories.

Each of the major story topics of 2010--recalls, FDA enforcement, job cuts, cargo theft, anti-counterfeiting--has themes that recur in the stories we've run. Follow the tracks of these themes for a hint at what's coming in 2011.

For the most part, traffic to these stories shows where your interest lies: Warning letters, consent decrees, product recalls and cargo theft are your proven favorites. In 2010 these topics had a marked increase in frequency as well as consequences, causing these bad-news stories to be the most popular on FiercePharmaManufacturing

But anti-counterfeiting is the outlier. Stories on this topic, curiously, draw little traffic, indicating little interest among readers. Yet counterfeiting meets the criteria: It's a big bad-news story with big consequences. And upcoming state and industry mandates will push fakes-fighting efforts right onto the factory floor, from the supply chain. So here's what I ponder as 2010 comes to a close: why the lack of interest? Email me to share your thoughts. - George Miller

P.S. FiercePharmaManufacturing won't be published next week as we pause to enjoy the holidays. We'll return to our regular publishing schedule on Tuesday, January 4.

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.